Testing Designated Clause Samples

Testing Designated. Positions (1) In addition to the general WSAP provisions, Seller shall determine if it has employees in TDPs as defined below and performing WSAP covered work. If Seller has no TDPs (potentially the case for uncleared construction subcontractors employees not possessing a Facility Clearance) the WSAP shall so state. If Seller has employees in TDPs performing WSAP covered work, then prior to beginning work under this Agreement, Seller shall provide the Subcontract Administrator with a list of all TDP employees, and Seller’s WSAP must comply with the provisions of 10 CFR Part 707 regarding TDPs. Thereafter, Seller shall notify the STR of any additions or deletions of employees in TDPs within 48 hours. (2) TDPs are defined as those positions involving certain high risk work listed in Part 707, access to classified information, construction, and crane operators, and any positions filled by employees holding an L- or Q-clearance. (3) Seller’s employees in TDPs who perform on-site will be subjected to the following drug testing by Company: (i) Random drug testing at the rates specified in 10 CFR 707.7, (ii) Drug testing as a result of an occurrence (see 10 CFR 707.9), and (iii) Drug testing for reasonable suspicion of illegal drug use (see 10 CFR 707.10). (4) Seller’s employees performing on-site work shall be placed in Company’s pool of employees for random drug testing, and these employees will be subject to testing by Company’s Occupational Health Services (OHS). Seller’s employee will be notified by Company’s representative when ▇▇▇▇▇▇’s employee is selected for random drug testing. Company’s representative will notify Company’s OHS when ▇▇▇▇▇▇’s employee has been notified of his/her duty to report to Company’s OHS. Upon notification by Company’s representative, ▇▇▇▇▇▇’s employee will have one and one-half hours to report to Company’s OHS.
View Source

Related to Testing Designated

  • ROADWAY DESIGN MISCELLANEOUS (ROADWAY)

  • Testing-the-Waters Materials If at any time following the distribution of any Written Testing-the-Waters Communication there occurred or occurs an event or development as a result of which such Written Testing-the-Waters Communication included or would include an untrue statement of a material fact or omitted or would omit to state a material fact necessary in order to make the statements therein, in the light of the circumstances existing at that subsequent time, not misleading, the Company will promptly notify the Representatives and will promptly amend or supplement, at its own expense, such Written Testing-the-Waters Communication to eliminate or correct such untrue statement or omission.

  • Schematic Design See Section 2, Part 1, Article 2.1.4, Paragraph 2.1.4.2.

  • Study Design This includes a discussion of the evaluation design employed including research questions and hypotheses; type of study design; impacted populations and stakeholders; data sources; and data collection; analysis techniques, including controls or adjustments for differences in comparison groups, controls for other interventions in the State and any sensitivity analyses, and limitations of the study.

  • Failure to Designate a Board Member In the absence of any designation from the Persons or groups with the right to designate a director as specified above, the director previously designated by them and then serving shall be reelected if still eligible to serve as provided herein.